Shareholder letter - Tuesday February 17, 2015

Link to document.

RegeneRx Pipeline

RegeneRx Biopharmaceuticals, Inc. is a clinical-stage drug development company focused on tissue protection, repair and regeneration with an extensive portfolio of product candidates for first-in-class therapeutic peptides.

Latest News:

March 3, 2015
Researchers at Henry Ford Hospital Propose Thymosin Beta 4 as Novel Way to Treat Neural Injury and Neurodegenerative Diseases

February 25, 2015
RegeneRx Receives Israeli Patent for Treating and Repairing Heart Damage

February 19, 2015
RegeneRx Updates Website

February 17, 2015
RegeneRx Releases Letter to Shareholders

January 28, 2015
RegeneRx and G-treeBNT Create Joint Venture to Develop RGN-259 in the U.S.

December 29, 2014
RegeneRx Partner Submits Phase IIB/III IND to Korean Health Authority for RGN-259 for the Treatment of Dry Eye Syndrome

November 25, 2014
Researchers Report Thymosin Beta 4 is Cardioprotective in Pulmonary Hypertension/Heart Failure Model